ATE356818T1 - Verbindungen - Google Patents
VerbindungenInfo
- Publication number
- ATE356818T1 ATE356818T1 AT02780910T AT02780910T ATE356818T1 AT E356818 T1 ATE356818 T1 AT E356818T1 AT 02780910 T AT02780910 T AT 02780910T AT 02780910 T AT02780910 T AT 02780910T AT E356818 T1 ATE356818 T1 AT E356818T1
- Authority
- AT
- Austria
- Prior art keywords
- links
- pharmaceuticals
- specifically
- relates
- receptor antagonists
- Prior art date
Links
- 229940123730 Orexin receptor antagonist Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
- A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Anesthesiology (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Addiction (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Valve-Gear Or Valve Arrangements (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0115862.5A GB0115862D0 (en) | 2001-06-28 | 2001-06-28 | Compounds |
| GBGB0130347.8A GB0130347D0 (en) | 2001-06-28 | 2001-12-19 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE356818T1 true ATE356818T1 (de) | 2007-04-15 |
Family
ID=26246260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02780910T ATE356818T1 (de) | 2001-06-28 | 2002-06-25 | Verbindungen |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US7423052B2 (de) |
| EP (1) | EP1406897B1 (de) |
| JP (1) | JP4328615B2 (de) |
| AT (1) | ATE356818T1 (de) |
| AU (1) | AU2002352633A1 (de) |
| DE (1) | DE60218852T2 (de) |
| ES (1) | ES2283609T3 (de) |
| GB (2) | GB0115862D0 (de) |
| WO (1) | WO2003002559A2 (de) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL158463A0 (en) * | 2001-05-05 | 2004-05-12 | Smithkline Beecham Plc | N-aroyl cyclic amines |
| JP2004534026A (ja) * | 2001-05-05 | 2004-11-11 | スミスクライン ビーチャム パブリック リミテッド カンパニー | オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体 |
| CN1549816A (zh) * | 2001-06-28 | 2004-11-24 | ʷ | 作为阿立新受体拮抗药的n-芳酰基环胺衍生物 |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| GB0127145D0 (en) * | 2001-11-10 | 2002-01-02 | Smithkline Beecham | Compounds |
| EP1465869B1 (de) | 2001-12-21 | 2013-05-15 | Exelixis Patent Company LLC | Modulatoren von lxr |
| US7482366B2 (en) | 2001-12-21 | 2009-01-27 | X-Ceptor Therapeutics, Inc. | Modulators of LXR |
| CA2495179A1 (en) | 2002-08-09 | 2004-02-19 | Astrazeneca Ab | Compounds having an activity at metabotropic glutamate receptors |
| DE60335891D1 (de) | 2002-10-11 | 2011-03-10 | Actelion Pharmaceuticals Ltd | Sulphonylaminoessigsaeure derivate und deren verwendung als orexin rezeptor antagoniste |
| HUE055434T2 (hu) | 2003-04-11 | 2021-11-29 | Ptc Therapeutics Inc | 1,2,4-Oxadiazol-benzoesav vegyület és alkalmazása nonszensz szupresszióra és betegség kezelésére |
| CA2520839A1 (en) | 2003-04-28 | 2004-11-11 | Actelion Pharmaceuticals Ltd | Quinoxalinone-3- one derivatives as orexin receptor antagonists |
| SG150539A1 (en) | 2004-02-18 | 2009-03-30 | Astrazeneca Ab | Tetrazole compounds and their use as metabotropic glutamate receptor antagonists |
| DK1751111T3 (en) | 2004-03-01 | 2015-02-09 | Actelion Pharmaceuticals Ltd | SUBSTITUTED 1,2,3,4-tetrahydroisoquinoline derivatives |
| US7501395B2 (en) | 2005-04-25 | 2009-03-10 | Eisai R & D Management Co., Ltd. | Method of screening for antianxiety drugs |
| GB0510142D0 (en) * | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds A1 |
| WO2007003961A2 (en) * | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
| EP2387995A1 (de) | 2006-03-30 | 2011-11-23 | PTC Therapeutics, Inc. | Verfahren zur Produktion von funktionellem Protein aus DNA mit Nonsense-Mutation und Behandlung von damit assoziierten Erkrankungen |
| JP2009543785A (ja) | 2006-07-14 | 2009-12-10 | メルク エンド カムパニー インコーポレーテッド | 架橋ジアゼパンオレキシン受容体アンタゴニスト |
| KR101404360B1 (ko) * | 2006-09-05 | 2014-06-09 | 교와 핫꼬 기린 가부시키가이샤 | 이미다졸 유도체 |
| KR20090077051A (ko) * | 2006-09-29 | 2009-07-14 | 액테리온 파마슈티칼 리미티드 | 3-아자-비시클로[3.1.0]헥산 유도체 |
| ES2357992T3 (es) | 2006-12-01 | 2011-05-04 | Actelion Pharmaceuticals Ltd. | Derivados de 3-heteroaril(amino o amido)-1-(bifenil o feniltiazolil)carbonilpiperidina como inhibidores del receptor de orexina. |
| PE20081229A1 (es) | 2006-12-01 | 2008-08-28 | Merck & Co Inc | Antagonistas de receptor de orexina de diazepam sustituido |
| CL2007003827A1 (es) * | 2006-12-28 | 2008-09-26 | Actelion Pharmaceuticals Ltd | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. |
| CL2008000836A1 (es) | 2007-03-26 | 2008-11-07 | Actelion Pharmaceuticals Ltd | Compuestos derivados de tiazolidina, antagonistas del receptor de orexina; composicion farmaceutica que los comprende; y su uso en el tratamiento de neurosis emocional, depresion grave, trastornos psicoticos, alzheimer, parkinson, dolor, entre otras. |
| CA2688776A1 (en) | 2007-05-18 | 2008-11-27 | Merck & Co., Inc. | Oxo bridged diazepan orexin receptor antagonists |
| JP2010528007A (ja) | 2007-05-23 | 2010-08-19 | メルク・シャープ・エンド・ドーム・コーポレイション | シクロプロピルピロリジンオレキシン受容体アンタゴニスト |
| MX2009012579A (es) * | 2007-05-23 | 2009-12-08 | Merck & Co Inc | Antagonistas piridil piperidina del receptor de orexina. |
| US20080306116A1 (en) * | 2007-06-08 | 2008-12-11 | Christ Andreas D | Aryloxazole, aryloxadiazole and benzimidazole derivatives |
| GB0712888D0 (en) * | 2007-07-03 | 2007-08-15 | Glaxo Group Ltd | Novel compounds |
| AU2008281399A1 (en) | 2007-07-27 | 2009-02-05 | Actelion Pharmaceuticals Ltd | 2-aza-bicyclo[3.3.0]octane derivatives |
| WO2009040730A2 (en) * | 2007-09-24 | 2009-04-02 | Actelion Pharmaceuticals Ltd | Pyrrolidines and piperidines as orexin receptor antagonists |
| EP2231647A4 (de) | 2007-10-19 | 2011-08-31 | Astrazeneca Ab | Tetrazolderivate als modulatoren von metabotropen glutamatrezeptoren (mglurs) |
| WO2009083903A1 (en) | 2007-12-28 | 2009-07-09 | Actelion Pharmaceuticals Ltd | Trisubstituted 3,4-dihydro-1h-isoquinolin compound, process for its preparation, and its use |
| JP5346043B2 (ja) * | 2008-02-12 | 2013-11-20 | エフ．ホフマン−ラ ロシュ アーゲー | ピペリジンスルホンアミド誘導体 |
| MX2010008993A (es) | 2008-02-21 | 2010-09-07 | Actelion Pharmaceuticals Ltd | Derivados de 2-aza-biciclo-[2.2.1]heptano. |
| GB0806536D0 (en) * | 2008-04-10 | 2008-05-14 | Glaxo Group Ltd | Novel compounds |
| WO2009133522A1 (en) * | 2008-04-30 | 2009-11-05 | Actelion Pharmaceuticals Ltd | Piperidine and pyrrolidine compounds |
| US8669272B2 (en) | 2008-10-21 | 2014-03-11 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| CA2739916A1 (en) * | 2008-10-21 | 2010-04-29 | Merck Sharp & Dohme Corp. | 2,5-disubstituted piperidine orexin receptor antagonists |
| US8357700B2 (en) | 2008-10-21 | 2013-01-22 | Merck Sharp & Dohme Corp. | 2,3-disubstituted piperidine orexin receptor antagonists |
| EA201170741A1 (ru) | 2008-12-02 | 2011-12-30 | Глэксо Груп Лимитед | Производные n-{[(1r,4s,6r)-3-(2-пиридинилкарбонил)-3-азабицикло[4.1.0]гепт-4-ил]метил}-2-гетероариламина и их применения |
| CA2746943A1 (en) | 2008-12-18 | 2010-07-15 | Boehringer Ingelheim International Gmbh | Serotonin 5-ht2b receptor inhibitors |
| GB0823467D0 (en) | 2008-12-23 | 2009-01-28 | Glaxo Group Ltd | Novel Compounds |
| EP2421850A1 (de) | 2009-04-24 | 2012-02-29 | Glaxo Group Limited | Als orexinantagonisten verwendete 3-azabicyclo[4.1.0]heptane |
| WO2011023578A1 (en) | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | 5-methyl-piperidine derivatives as orexin receptor antagonists for the treatment of sleep disorder |
| WO2011023585A1 (en) | 2009-08-24 | 2011-03-03 | Glaxo Group Limited | Piperidine derivatives used as orexin antagonists |
| WO2012063207A1 (en) * | 2010-11-10 | 2012-05-18 | Actelion Pharmaceuticals Ltd | Lactam derivatives useful as orexin receptor antagonists |
| WO2012089607A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Novel compounds with a 3a-azabicyclo [4.1.0] heptane core acting on orexin receptors |
| WO2012089606A1 (en) | 2010-12-28 | 2012-07-05 | Glaxo Group Limited | Azabicyclo [4.1.0] hept - 4 - yl derivatives as human orexin receptor antagonists |
| AU2012311057B2 (en) | 2011-09-19 | 2015-09-17 | Suven Life Sciences Limited | Heteroaryl compounds as 5-HT4 receptor ligands |
| AR088352A1 (es) | 2011-10-19 | 2014-05-28 | Merck Sharp & Dohme | Antagonistas del receptor de 2-piridiloxi-4-nitrilo orexina |
| WO2013068935A1 (en) * | 2011-11-08 | 2013-05-16 | Actelion Pharmaceuticals Ltd | 2-(1,2,3-triazol-2-yl)benzamide and 3-(1,2,3-triazol-2-yl)picolinamide derivatives as orexin receptor antagonists |
| US9440982B2 (en) | 2012-02-07 | 2016-09-13 | Eolas Therapeutics, Inc. | Substituted prolines/piperidines as orexin receptor antagonists |
| KR20140124398A (ko) | 2012-02-07 | 2014-10-24 | 이올라스 테라퓨틱스, 인코포레이티드 | 오렉신 수용체 길항제로서 치환된 프롤린 / 피페리딘 |
| SI2855453T1 (sl) | 2012-06-04 | 2017-05-31 | Actelion Pharmaceuticals Ltd. | Benzimidazol-prolinski derivati |
| DK2862860T3 (en) * | 2012-06-15 | 2017-01-30 | Taisho Pharmaceutical Co Ltd | 1,3-oxazolidine or 1,3-oxazinan compounds as orexin receptor antagonists |
| CA2876249A1 (en) | 2012-06-15 | 2013-12-19 | Taisho Pharmaceutical Co., Ltd. | Branched chain alkyl heteroaromatic ring derivative |
| EA201500399A1 (ru) | 2012-10-10 | 2015-09-30 | Актелион Фармасьютиклз Лтд. | Антагонисты рецептора орексина, которые представляют собой производные [орто-би-(гетеро)арил]-[2-(мета-би-(гетеро)арил)пирролидин-1-ил]метанона |
| TW201444798A (zh) | 2013-02-28 | 2014-12-01 | 必治妥美雅史谷比公司 | 作爲強效ｒｏｃｋ１及ｒｏｃｋ２抑制劑之苯基吡唑衍生物 |
| US9828345B2 (en) | 2013-02-28 | 2017-11-28 | Bristol-Myers Squibb Company | Phenylpyrazole derivatives as potent ROCK1 and ROCK2 inhibitors |
| CA2902135A1 (en) | 2013-03-12 | 2014-09-18 | Actelion Pharmaceuticals Ltd | Azetidine amide derivatives as orexin receptor antagonists |
| WO2015018029A1 (en) * | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Oxazole orexin receptor antagonists |
| WO2015018027A1 (en) * | 2013-08-08 | 2015-02-12 | Merck Sharp & Dohme Corp. | Thiazole orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| UA119549C2 (uk) | 2013-12-03 | 2019-07-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ТА ЇЇ ЗАСТОСУВАННЯ ЯК АНТАГОНІСТА ОРЕКСИНОВОГО РЕЦЕПТОРА |
| PT3077391T (pt) | 2013-12-04 | 2018-11-26 | Idorsia Pharmaceuticals Ltd | Utilização de derivados de benzimidazol-prolina |
| JP2017024990A (ja) * | 2013-12-13 | 2017-02-02 | 大正製薬株式会社 | オキサゾリジン及びオキサジナン誘導体 |
| JP5907310B2 (ja) * | 2013-12-13 | 2016-04-26 | 大正製薬株式会社 | オキサジナン化合物の結晶形及びその製造方法 |
| CN106455571A (zh) | 2014-03-06 | 2017-02-22 | Ptc医疗公司 | 1,2,4‑噁二唑苯甲酸的药物组合物和盐 |
| UY36272A (es) | 2014-08-13 | 2016-02-29 | Eolas Therapeutics Inc | Difluoropirrolidinas como moduladores de los receptores de orexinas |
| WO2016086357A1 (en) | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Methyl oxazole orexin receptor antagonists |
| WO2016086358A1 (en) | 2014-12-02 | 2016-06-09 | Merck Sharp & Dohme Corp. | Hydroxymethyl piperidine orexin receptor antagonists |
| WO2016095204A1 (en) * | 2014-12-19 | 2016-06-23 | Merck Sharp & Dohme Corp. | Pyrrolidine orexin receptor antagonists |
| JP2018188364A (ja) * | 2015-10-02 | 2018-11-29 | 大正製薬株式会社 | 複素芳香環誘導体 |
| CN108348527A (zh) | 2015-10-30 | 2018-07-31 | Ptc医疗公司 | 用于治疗癫痫的方法 |
| CA3013927C (en) | 2016-02-12 | 2024-02-13 | Astrazeneca Ab | Halo-substituted piperidines as orexin receptor modulators |
| EP3454857A1 (de) | 2016-05-10 | 2019-03-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Verfahren und pharmazeutische zusammensetzungen zur behandlung entzündlicher augenkrankheiten |
| WO2020007964A1 (en) | 2018-07-05 | 2020-01-09 | Idorsia Pharmaceuticals Ltd | 2-(2-azabicyclo[3.1.0]hexan-1-yl)-1h-benzimidazole derivatives |
| WO2020099511A1 (en) | 2018-11-14 | 2020-05-22 | Idorsia Pharmaceuticals Ltd | Benzimidazole-2-methyl-morpholine derivatives |
| EP3972588A4 (de) | 2019-06-04 | 2023-05-31 | Hager Biosciences, LLC | Imidazolderivate, zusammensetzungen und verfahren als orexin-antagonisten |
| CN110437092B (zh) * | 2019-07-11 | 2022-06-10 | 泓博智源(开原)药业有限公司 | 一种替格瑞洛关键中间体芳族环丙烷酰胺的制备方法 |
| AR129309A1 (es) | 2022-05-13 | 2024-08-07 | Idorsia Pharmaceuticals Ltd | Derivados de hidrazina-n-carboxamida cíclica sustituida con tiazoloaril-metilo |
| US20260021059A1 (en) * | 2022-07-19 | 2026-01-22 | Rutgers, The State University Of New Jersey | Therapeutic combinations and methods |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3810097B2 (ja) * | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−２−イルカルボニル複素環式化合物誘導体 |
| IL111730A (en) * | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives processes for the preparation thereof and pharmaceutical compositions containing the same |
| AR016817A1 (es) | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| EP1075478B1 (de) | 1998-05-08 | 2003-04-16 | SmithKline Beecham plc | Phenylurea und phenylthio urea derivate |
| ES2230864T3 (es) | 1998-07-24 | 2005-05-01 | Teijin Limited | Derivados del acido antranilico. |
| IL141063A (en) | 1998-08-07 | 2005-06-19 | Applied Research Systems | Derivatives of pyrrolidine-2-carboxylic acid and piperidine-2-carboxylic acids and pharmaceutical compositions comprising said derivatives for treating infertility |
| WO2000012077A1 (en) | 1998-09-01 | 2000-03-09 | Bristol-Myers Squibb Company | Potassium channel inhibitors and method |
| US6326379B1 (en) | 1998-09-16 | 2001-12-04 | Bristol-Myers Squibb Co. | Fused pyridine inhibitors of cGMP phosphodiesterase |
| SK7582001A3 (en) | 1998-12-18 | 2002-03-05 | Schering Corp | Compound, method of therapy and pharmaceutical composition comprising the same, and its use for farnesyl protein transferase inhibition |
| WO2000047576A1 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Cinnamide derivatives as orexin-1 receptors antagonists |
| WO2000047580A2 (en) | 1999-02-12 | 2000-08-17 | Smithkline Beecham Plc | Phenyl urea and phenyl thiourea derivatives |
| MXPA01008606A (es) | 1999-02-26 | 2003-05-05 | Merck & Co Inc | Compuestos de sulfonamida novedosos y uso de los mismos. |
| EP1185508A2 (de) | 1999-05-24 | 2002-03-13 | Cor Therapeutics, Inc. | Inhibitoren von faktor xa |
| MY125533A (en) | 1999-12-06 | 2006-08-30 | Bristol Myers Squibb Co | Heterocyclic dihydropyrimidine compounds |
| WO2001044228A2 (fr) | 1999-12-14 | 2001-06-21 | Sanofi-Synthelabo | Derives de quinazolinedione et phtalimide, leurs preparations et leurs applications en therapeutique |
| HUP0202263A3 (en) | 1999-12-27 | 2003-02-28 | Japan Tobacco Inc | Benzimidazole, indole and imidazo-pyridine derivatives and pharmaceutical compositions containing them |
| ATE293101T1 (de) | 2000-06-16 | 2005-04-15 | Smithkline Beecham Plc | Piperidine zur verwendung als orexin rezeptor antagonisten |
| JP4246490B2 (ja) | 2000-11-28 | 2009-04-02 | スミスクライン ビーチャム ピー エル シー | オレキシン受容体のアンタゴニストとしてのモルホリン誘導体 |
| JP2004534026A (ja) | 2001-05-05 | 2004-11-11 | スミスクライン ビーチャム パブリック リミテッド カンパニー | オレキシン受容体アンタゴニストとしてのｎ−アロイルサイクリックアミン誘導体 |
| IL158463A0 (en) | 2001-05-05 | 2004-05-12 | Smithkline Beecham Plc | N-aroyl cyclic amines |
| GB0115862D0 (en) | 2001-06-28 | 2001-08-22 | Smithkline Beecham Plc | Compounds |
| CN1549816A (zh) | 2001-06-28 | 2004-11-24 | ʷ | 作为阿立新受体拮抗药的n-芳酰基环胺衍生物 |
| US20060040937A1 (en) | 2002-09-18 | 2006-02-23 | Glaxo Group Limited | N-aroyl cyclic amines as orexin receptor antagonists |
-
2001
- 2001-06-28 GB GBGB0115862.5A patent/GB0115862D0/en not_active Ceased
- 2001-12-19 GB GBGB0130347.8A patent/GB0130347D0/en not_active Ceased
-
2002
- 2002-06-25 ES ES02780910T patent/ES2283609T3/es not_active Expired - Lifetime
- 2002-06-25 EP EP02780910A patent/EP1406897B1/de not_active Expired - Lifetime
- 2002-06-25 DE DE60218852T patent/DE60218852T2/de not_active Expired - Lifetime
- 2002-06-25 US US10/481,083 patent/US7423052B2/en not_active Expired - Fee Related
- 2002-06-25 AU AU2002352633A patent/AU2002352633A1/en not_active Abandoned
- 2002-06-25 WO PCT/EP2002/007007 patent/WO2003002559A2/en not_active Ceased
- 2002-06-25 AT AT02780910T patent/ATE356818T1/de not_active IP Right Cessation
- 2002-06-25 JP JP2003508940A patent/JP4328615B2/ja not_active Expired - Fee Related
-
2008
- 2008-07-08 US US12/169,164 patent/US7943645B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2003002559A3 (en) | 2003-08-28 |
| WO2003002559A2 (en) | 2003-01-09 |
| EP1406897A2 (de) | 2004-04-14 |
| ES2283609T3 (es) | 2007-11-01 |
| US20090082390A1 (en) | 2009-03-26 |
| GB0130347D0 (en) | 2002-02-06 |
| JP2005501026A (ja) | 2005-01-13 |
| US20040215014A1 (en) | 2004-10-28 |
| JP4328615B2 (ja) | 2009-09-09 |
| US7943645B2 (en) | 2011-05-17 |
| US7423052B2 (en) | 2008-09-09 |
| AU2002352633A1 (en) | 2003-03-03 |
| EP1406897B1 (de) | 2007-03-14 |
| DE60218852T2 (de) | 2007-12-13 |
| GB0115862D0 (en) | 2001-08-22 |
| DE60218852D1 (de) | 2007-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60218852D1 (de) | Verbindungen | |
| ATE344261T1 (de) | Cyclische n-aroylamine als orexinrezeptorantagonisten | |
| NO20035739L (no) | N-aroyl syklisk aminderivater som orexin reseptorantagonister | |
| DE60228487D1 (de) | Ethylenediaminderivate und ihre verwendung als orexinrezeptorantagonisten | |
| WO2004069793A3 (en) | Novel 2-substituted cyclic amines as calcium sensing receptor modulators | |
| TR200102029T2 (tr) | 1-Heterosiklil ikameli diarilaminler. | |
| SMP200600024B (it) | 2,6-Biseteroaril-4-amminopirimidine come antagonisti del recettore dell'adenosina | |
| BR0115436A (pt) | Compostos de piperazinilpirazina atuando como antagonistas do receptor 5ht-2 de serotonina | |
| NO20021450D0 (no) | Cykliske aminforbindelser som CCR5 antagonister | |
| DE60224521D1 (de) | N-aroyl zyklische amine | |
| ATE372768T1 (de) | N-(2-arylethyl) benzylamine als 5-ht6 rezeptor- antagoniste | |
| ATE360629T1 (de) | Photoaktivierbare stickstoffbasen | |
| UY3450Q (es) | Botella | |
| BR0115400A (pt) | Compostos de piperazinilpirazina atuando como agonistas ou antagonistas do receptor 5ht-2 de serotonina | |
| BRPI0414598A (pt) | indóis substituìdos | |
| NO20040028L (no) | Substituerte anilinske piperidiner som MCH-selektive antagonister | |
| CY1107368T1 (el) | Νεα παραγωγα 4-βενζυλιδενο-πιπεριδινης | |
| EA200701122A1 (ru) | Потенциаторы рецепторов глутамата | |
| CY1107254T1 (el) | Μη πεπτιδικοι ανταγωνιστες της ωραδυκινινης και φαρμακευτικες συνθεσεις αυτων | |
| ATE422198T1 (de) | Arylsulfonylnaphthalinderivate als 5ht2a- antagonisten | |
| DE60238709D1 (de) | 4-piperidinylalkylamin-derivate, antagonisten von muscarinrezeptoren | |
| NO20040877L (no) | Cyklisk aminforbindelse. | |
| ITMI20031292A1 (it) | Derivati biciclici nk-2 antagonisti selettivi. | |
| DE60015187D1 (de) | Urotensin-ii rezeptorantagonisten | |
| DE60322237D1 (de) | 6h-thienä2,3-büpyrrolderivate als antagonisten des gonadotropin-freisetzenden hormons (gnrh) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |